Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2025-12-26 @ 9:40 PM
Study NCT ID:
NCT05425004
Status:
RECRUITING
Last Update Posted:
2025-05-22
First Post:
2022-06-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Sponsor:
Baptist Health South Florida
Organization:
Study Overview
Official Title:
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Status:
RECRUITING
Status Verified Date:
2025-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: